<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antioxidants (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antioxidants (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2840</journal-id><journal-id journal-id-type="pmc-domain">antiox</journal-id><journal-id journal-id-type="publisher-id">antioxidants</journal-id><journal-title-group><journal-title>Antioxidants</journal-title></journal-title-group><issn pub-type="epub">2076-3921</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10451270</article-id><article-id pub-id-type="pmcid-ver">PMC10451270.1</article-id><article-id pub-id-type="pmcaid">10451270</article-id><article-id pub-id-type="pmcaiid">10451270</article-id><article-id pub-id-type="pmid">37627479</article-id><article-id pub-id-type="doi">10.3390/antiox12081484</article-id><article-id pub-id-type="publisher-id">antioxidants-12-01484</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Paraoxonase/Arylesterase Activity of Serum Paraoxonase-1 and Schizophrenia: A Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8396-0968</contrib-id><name name-style="western"><surname>Zinellu</surname><given-names initials="A">Angelo</given-names></name><xref rid="af1-antioxidants-12-01484" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sedda</surname><given-names initials="S">Stefania</given-names></name><xref rid="af1-antioxidants-12-01484" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8699-1412</contrib-id><name name-style="western"><surname>Mangoni</surname><given-names initials="AA">Arduino A.</given-names></name><xref rid="af2-antioxidants-12-01484" ref-type="aff">2</xref><xref rid="af3-antioxidants-12-01484" ref-type="aff">3</xref><xref rid="c1-antioxidants-12-01484" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Steullet</surname><given-names initials="P">Pascal</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antioxidants-12-01484"><label>1</label>Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; <email>azinellu@uniss.it</email> (A.Z.); <email>s.sedda4@studenti.uniss.it</email> (S.S.)</aff><aff id="af2-antioxidants-12-01484"><label>2</label>Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia</aff><aff id="af3-antioxidants-12-01484"><label>3</label>Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, SA 5042, Australia</aff><author-notes><corresp id="c1-antioxidants-12-01484"><label>*</label>Correspondence: <email>arduino.mangoni@flinders.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2023</year></pub-date><volume>12</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">443988</issue-id><elocation-id>1484</elocation-id><history><date date-type="received"><day>16</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>18</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-28 03:25:16.663"><day>28</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="antioxidants-12-01484.pdf"/><abstract><p>The presence of a pro-oxidant state in patients with schizophrenia may account for the increased risk of atherosclerosis and cardiovascular disease in this group and supports the potential utility of circulating biomarkers of oxidative stress for risk stratification and management. We investigated this issue by conducting a systematic review and meta-analysis of the association between the circulating concentrations of paraoxonase-1, an antioxidant calcium-dependent high-density lipoprotein (HDL)-associated esterase, with paraoxonase and arylesterase activity in schizophrenia. We searched electronic databases from inception to 31 May 2023 for studies investigating paraoxonase-1 in patients with schizophrenia and healthy controls and assessed the risk of bias and the certainty of evidence (PROSPERO registration number: CRD42023435442). Thirteen studies were identified for analysis. There were no significant between-group differences in paraoxonase (standard mean difference, SMD = 0.12, 95% CI &#8722;0.23 to 0.48, <italic toggle="yes">p</italic> = 0.50; extremely low certainty of evidence) or arylesterase activity (SMD = &#8722;0.08, 95% CI &#8722;0.39 to 0.23, <italic toggle="yes">p</italic> = 0.61; very low certainty of evidence). However, in meta-regression and subgroup analysis we observed significant associations between the SMD of paraoxonase and age (<italic toggle="yes">p</italic> = 0.003), HDL&#8211;cholesterol (<italic toggle="yes">p</italic> = 0.029), and study country (<italic toggle="yes">p</italic> = 0.04), and the SMD of arylesterase and age (<italic toggle="yes">p</italic> = 0.007), body mass index (<italic toggle="yes">p</italic> = 0.012), HDL&#8211;cholesterol (<italic toggle="yes">p</italic> = 0.002), and pharmacological treatment for schizophrenia (<italic toggle="yes">p</italic> &lt; 0.001). In the absence of overall between-group differences, our systematic review and meta-analysis suggests that alterations in paraoxonase-1 may reflect a pro-oxidant state in specific subgroups of patients with schizophrenia that require further assessment in appropriately designed studies.</p></abstract><kwd-group><kwd>schizophrenia</kwd><kwd>paraoxonase-1</kwd><kwd>paraoxonase</kwd><kwd>arylesterase</kwd><kwd>oxidative stress</kwd><kwd>HDL cholesterol</kwd><kwd>cardiovascular disease</kwd><kwd>atherosclerosis</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-antioxidants-12-01484"><title>1. Introduction</title><p>There is increasing evidence from experimental models and human studies that schizophrenia and associated psychiatric disorders, e.g., schizoaffective disorder, are characterised by a dysregulated immune system and a pro-oxidative state [<xref rid="B1-antioxidants-12-01484" ref-type="bibr">1</xref>,<xref rid="B2-antioxidants-12-01484" ref-type="bibr">2</xref>,<xref rid="B3-antioxidants-12-01484" ref-type="bibr">3</xref>,<xref rid="B4-antioxidants-12-01484" ref-type="bibr">4</xref>,<xref rid="B5-antioxidants-12-01484" ref-type="bibr">5</xref>]. Local inflammation (neuroinflammation) and abnormalities in the balance between antioxidant and pro-oxidant mechanisms are likely to be involved in the pathogenesis and the progression of schizophrenia [<xref rid="B6-antioxidants-12-01484" ref-type="bibr">6</xref>,<xref rid="B7-antioxidants-12-01484" ref-type="bibr">7</xref>,<xref rid="B8-antioxidants-12-01484" ref-type="bibr">8</xref>,<xref rid="B9-antioxidants-12-01484" ref-type="bibr">9</xref>]. However, the co-existence of a systemic pro-inflammatory and pro-oxidant state may also account for the increased risk of several other disease states in patients with schizophrenia, which imposes a further health and financial burden to this patient group as well as to healthcare systems worldwide [<xref rid="B10-antioxidants-12-01484" ref-type="bibr">10</xref>,<xref rid="B11-antioxidants-12-01484" ref-type="bibr">11</xref>,<xref rid="B12-antioxidants-12-01484" ref-type="bibr">12</xref>,<xref rid="B13-antioxidants-12-01484" ref-type="bibr">13</xref>]. For example, several epidemiological studies have recently reported a significant increase in the risk of atherosclerosis and cardiovascular disease, conditions that are also characterised by a pro-inflammatory and pro-oxidant state, in patients with schizophrenia [<xref rid="B14-antioxidants-12-01484" ref-type="bibr">14</xref>,<xref rid="B15-antioxidants-12-01484" ref-type="bibr">15</xref>,<xref rid="B16-antioxidants-12-01484" ref-type="bibr">16</xref>,<xref rid="B17-antioxidants-12-01484" ref-type="bibr">17</xref>,<xref rid="B18-antioxidants-12-01484" ref-type="bibr">18</xref>]. These observations support the proposition that oxidative stress plays a critical pathophysiological role in the onset and the progression of schizophrenia and in the association between schizophrenia and atherosclerosis and cardiovascular disease. Furthermore, they suggest that the identification of circulating biomarkers of oxidative stress may be useful for risk stratification as well as for the monitoring of the clinical effects of specific antipsychotic and cardioprotective treatments in patients with schizophrenia [<xref rid="B1-antioxidants-12-01484" ref-type="bibr">1</xref>,<xref rid="B19-antioxidants-12-01484" ref-type="bibr">19</xref>,<xref rid="B20-antioxidants-12-01484" ref-type="bibr">20</xref>,<xref rid="B21-antioxidants-12-01484" ref-type="bibr">21</xref>,<xref rid="B22-antioxidants-12-01484" ref-type="bibr">22</xref>,<xref rid="B23-antioxidants-12-01484" ref-type="bibr">23</xref>,<xref rid="B24-antioxidants-12-01484" ref-type="bibr">24</xref>,<xref rid="B25-antioxidants-12-01484" ref-type="bibr">25</xref>]. One such potential biomarker is paraoxonase-1, an antioxidant calcium-dependent high-density lipoprotein (HDL)-associated glycoprotein esterase containing 354 amino acids which possesses a combined paraoxonase and arylesterase activity [<xref rid="B26-antioxidants-12-01484" ref-type="bibr">26</xref>]. The hydrophobic sequence located in the N-terminal region of paraoxonase-1 favors its interaction with HDL [<xref rid="B27-antioxidants-12-01484" ref-type="bibr">27</xref>,<xref rid="B28-antioxidants-12-01484" ref-type="bibr">28</xref>].</p><p>The paraoxonase multi-gene family is widely expressed in mammals and includes paraoxonase-1, paraoxonase-2, and paraoxonase-3 [<xref rid="B26-antioxidants-12-01484" ref-type="bibr">26</xref>]. Paraoxonase-1 and paraoxonase-3 are mainly present in the circulation whereas paraoxonase-2 is located intracellularly [<xref rid="B29-antioxidants-12-01484" ref-type="bibr">29</xref>]. Paraoxonase-1 is the most studied in basic research and clinical studies as it has a wider range of substrates and circulating concentrations that are at least twofold those of paraoxonase-3 [<xref rid="B30-antioxidants-12-01484" ref-type="bibr">30</xref>,<xref rid="B31-antioxidants-12-01484" ref-type="bibr">31</xref>]. Consequently, the assessment of circulating paraoxonase-1 likely reflects the majority of circulating paraoxonase activity. This includes paraoxonase activity (which uses the substrate paraoxon) and arylesterase activity (which uses the substrate phenylacetate) [<xref rid="B31-antioxidants-12-01484" ref-type="bibr">31</xref>,<xref rid="B32-antioxidants-12-01484" ref-type="bibr">32</xref>,<xref rid="B33-antioxidants-12-01484" ref-type="bibr">33</xref>,<xref rid="B34-antioxidants-12-01484" ref-type="bibr">34</xref>]. A number of studies have recently highlighted the potential clinical utility of measuring the circulating concentrations of paraoxonase-1 in several disease states, particularly in autoimmune, circulatory, and respiratory disorders [<xref rid="B35-antioxidants-12-01484" ref-type="bibr">35</xref>,<xref rid="B36-antioxidants-12-01484" ref-type="bibr">36</xref>,<xref rid="B37-antioxidants-12-01484" ref-type="bibr">37</xref>,<xref rid="B38-antioxidants-12-01484" ref-type="bibr">38</xref>,<xref rid="B39-antioxidants-12-01484" ref-type="bibr">39</xref>,<xref rid="B40-antioxidants-12-01484" ref-type="bibr">40</xref>,<xref rid="B41-antioxidants-12-01484" ref-type="bibr">41</xref>]. Paraoxonase-1 exerts a critical role in maintaining the antioxidant effects of HDL, and its reduction is believed to promote a dysfunctional HDL which, in turn, can paradoxically favor the onset of atherosclerosis and other inflammatory conditions [<xref rid="B28-antioxidants-12-01484" ref-type="bibr">28</xref>,<xref rid="B42-antioxidants-12-01484" ref-type="bibr">42</xref>,<xref rid="B43-antioxidants-12-01484" ref-type="bibr">43</xref>,<xref rid="B44-antioxidants-12-01484" ref-type="bibr">44</xref>,<xref rid="B45-antioxidants-12-01484" ref-type="bibr">45</xref>,<xref rid="B46-antioxidants-12-01484" ref-type="bibr">46</xref>]. For example, in a meta-analysis of six observational studies including a total of 15,064 subjects, the pooled age-adjusted risk ratio (RR) for any cardiovascular event per each one standard deviation (SD) increase in paraoxonase-1 concentration was 0.87 (95% confidence intervals, CI, 0.80 to 0.96, <italic toggle="yes">p</italic> = 0.005) [<xref rid="B47-antioxidants-12-01484" ref-type="bibr">47</xref>]. Therefore, a reduction in paraoxonase-1 concentration might account for a systemic pro-oxidative state as well as the increased cardiovascular risk observed in patients with schizophrenia.</p><p>We investigated this issue by conducting a systematic review and meta-analysis of studies reporting circulating paraoxonase-1 concentrations in patients with schizophrenia and healthy controls and assessing possible associations between the effect size of paraoxonase and arylesterase activity and pre-defined variables. We speculated that schizophrenia is associated with a significant reduction in the enzymatic activity of paraoxonase and arylesterase, reflecting the presence of a pro-oxidant state in this patient group.</p></sec><sec sec-type="methods" id="sec2-antioxidants-12-01484"><title>2. Methods</title><sec id="sec2dot1-antioxidants-12-01484"><title>2.1. Literature Search</title><p>We searched PubMed, Web of Science, and Scopus from inception to 31 May 2023. The following terms and their combination were used in the systematic search: &#8220;paraoxonase&#8221; or &#8220;PON&#8221; or &#8220;arylesterase&#8221; and &#8220;schizophrenia&#8221; or &#8220;acute psychotic disorder&#8221; or &#8220;schizoaffective disorder&#8221;. Two independent investigators screened the abstracts and, if relevant, individual articles according to the following criteria: (i) the assessment of plasma or serum paraoxonase-1 concentrations; (ii) the assessment of paraoxonase and/or arylesterase activity in patients with schizophrenia and in healthy controls (case-control design); (iii) the assessment of 10 or more patients; (iv) the use of English language; and (v) the availability of the full-text of the article. The 2 investigators also searched the references of individual articles for additional studies. A third investigator was involved in case of disagreement.</p><p>Extracted parameters included: first author, year of publication, study country, number of participants, age, sex distribution, body mass index, serum concentrations of paraoxonase, arylesterase, and HDL&#8211;cholesterol, and pharmacological treatment for schizophrenia. We assessed the risk of bias (Joanna Briggs Institute critical appraisal checklist for analytical studies; studies addressing &#8805; 75% checklist items were adjudicated as low risk [<xref rid="B48-antioxidants-12-01484" ref-type="bibr">48</xref>]) and the certainty of evidence (grades of recommendation, assessment, development and evaluation, GRADE, working group system [<xref rid="B49-antioxidants-12-01484" ref-type="bibr">49</xref>,<xref rid="B50-antioxidants-12-01484" ref-type="bibr">50</xref>]). We fully complied with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 statement (<xref rid="app1-antioxidants-12-01484" ref-type="app">Supplementary Tables S1 and S2</xref>) [<xref rid="B51-antioxidants-12-01484" ref-type="bibr">51</xref>] and registered our review in the International Prospective Register of Systematic Reviews (PROSPERO registration number: CRD42023435442).</p></sec><sec id="sec2dot2-antioxidants-12-01484"><title>2.2. Statistical Analysis</title><p>Forest plots of standardized mean differences (SMD) and 95% confidence intervals (CIs) were generated to evaluate the presence of differences in paraoxonase-1 concentrations between patients with schizophrenia and healthy controls (statistical significance set at <italic toggle="yes">p</italic> &lt; 0.05). Means and standard deviations were extrapolated from medians and interquartile ranges or ranges [<xref rid="B52-antioxidants-12-01484" ref-type="bibr">52</xref>,<xref rid="B53-antioxidants-12-01484" ref-type="bibr">53</xref>], or using the Graph Data Extractor software (San Diego, CA, USA). The presence of between-study SMD heterogeneity was assessed using the Q statistic (statistical significance set at <italic toggle="yes">p</italic> &lt; 0.10) and the I<sup>2</sup> statistic. [<xref rid="B54-antioxidants-12-01484" ref-type="bibr">54</xref>,<xref rid="B55-antioxidants-12-01484" ref-type="bibr">55</xref>,<xref rid="B56-antioxidants-12-01484" ref-type="bibr">56</xref>]. The stability of the effect size was assessed in a sensitivity analysis [<xref rid="B57-antioxidants-12-01484" ref-type="bibr">57</xref>]. Publication bias was assessed with the Begg&#8217;s and Egger&#8217;s tests [<xref rid="B58-antioxidants-12-01484" ref-type="bibr">58</xref>,<xref rid="B59-antioxidants-12-01484" ref-type="bibr">59</xref>] and the &#8220;trim-and-fill&#8221; method [<xref rid="B60-antioxidants-12-01484" ref-type="bibr">60</xref>]. Univariate meta-regression and subgroup analyses were conducted to investigate the presence of associations between the effect size and several pre-defined variables: age, proportion of males, year of publication, study country, sample size, body mass index, HDL&#8211;cholesterol concentrations, and pharmacological treatment for schizophrenia. Statistical analyses were performed using Stata 14 (STATA Corp, College Station, TX, USA).</p></sec></sec><sec sec-type="results" id="sec3-antioxidants-12-01484"><title>3. Results</title><sec id="sec3dot1-antioxidants-12-01484"><title>3.1. Systematic Search</title><p>A flow chart of the screening process is described in <xref rid="antioxidants-12-01484-f001" ref-type="fig">Figure 1</xref>. After identifying a total of 123 articles, 106 were excluded as they were either duplicates or not relevant to the search strategy. After a full-text revision of the remaining 17 articles, 4 were further excluded (missing information: 2 studies; duplicate data: 1 study; paraoxonase-1 assay not performed as enzyme activity: 1 study), leaving 13 studies for final analysis [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>]. The selected studies, published between 2007 and 2018, investigated a total of 825 patients with schizophrenia with a mean age of 36 years (66% males) and 725 healthy controls with a mean age of 36 years (58% males; <xref rid="antioxidants-12-01484-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot2-antioxidants-12-01484"><title>3.2. Paraoxonase Activity</title><p>Nine studies that included 13 study groups investigated paraoxonase activity in a total of 570 patients with schizophrenia (mean age 37 years, 65% males) and 512 healthy controls (mean age 38 years, 59% males) [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>]. Seven studies were conducted in Turkey [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>], one in Romania [<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>], and one in Tunisia [<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>]. Patients received pharmacological treatment for schizophrenia in 11 study groups [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>] and no treatment in the remaining 2 [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>]. The enzymatic activity of paraoxonase was evaluated by using paraoxon as a substrate in all the selected studies [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>]. Furthermore, all studies had a low risk of bias (<xref rid="app1-antioxidants-12-01484" ref-type="app">Supplementary Table S3</xref>) [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p><p>In forest plots, paraoxonase activity was non-significantly different between control subjects and patients with schizophrenia (SMD = 0.12, 95% CI &#8722;0.23 to 0.48, <italic toggle="yes">p</italic> = 0.50; I<sup>2</sup> = 87.1%, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="antioxidants-12-01484-f002" ref-type="fig">Figure 2</xref>). A sensitivity analysis showed stability of the effect size, with the corresponding SMD values ranging between &#8722;0.06 and 0.13 (<xref rid="antioxidants-12-01484-f003" ref-type="fig">Figure 3</xref>).</p><p>There was a significant publication bias with the Begg&#8217;s test (<italic toggle="yes">p</italic> = 0.04) but not with the Egger&#8217;s test (<italic toggle="yes">p</italic> = 0.10). The &#8220;trim-and-fill&#8221; procedure identified four studies to be added to the funnel plot (<xref rid="antioxidants-12-01484-f004" ref-type="fig">Figure 4</xref>). The resulting SMD was &#8722;0.23 (95% CI &#8722;0.62 to 0.16, <italic toggle="yes">p</italic> = 0.25).</p><p>Non-significant associations were observed between the effect size of paraoxonase activity and the proportion of males (t = &#8722;1.68, <italic toggle="yes">p</italic> = 0.13), the publication year (t = 0.76, <italic toggle="yes">p</italic> = 0.46), the sample size (t = &#8722;0.79, <italic toggle="yes">p</italic> = 0.45), or the body mass index (t = 2.24, <italic toggle="yes">p</italic> = 0.052) in the meta-regression analysis. By contrast, there was a significant negative association with the patient/control age ratio (t = &#8722;3.88, <italic toggle="yes">p</italic> = 0.003; <xref rid="antioxidants-12-01484-f005" ref-type="fig">Figure 5</xref>A) and a significant positive association between the effect size and the patient/control HDL&#8211;cholesterol ratio (t = 2.59, <italic toggle="yes">p</italic> = 0.029; <xref rid="antioxidants-12-01484-f006" ref-type="fig">Figure 6</xref>A). These associations were also confirmed using the metacum analysis command (<xref rid="antioxidants-12-01484-f005" ref-type="fig">Figure 5</xref>B and <xref rid="antioxidants-12-01484-f006" ref-type="fig">Figure 6</xref>B).</p><p>In a subgroup analysis, the SMD was significantly smaller (<italic toggle="yes">p</italic> = 0.04) in studies conducted in Turkey (SMD = &#8722;0.12, 95% CI &#8722;0.39 to 0.16, <italic toggle="yes">p</italic> = 0.41; I<sup>2</sup> = 70.8%, <italic toggle="yes">p</italic> &lt; 0.001) than those conducted in other countries (SMD = 1.09, 95% CI &#8722;0.64 to 2.83, <italic toggle="yes">p</italic> = 0.22; I<sup>2</sup> = 96.7%, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="antioxidants-12-01484-f007" ref-type="fig">Figure 7</xref>). There were non-significant differences (<italic toggle="yes">p</italic> = 0.58) in the pooled SMD between studies performed in untreated patients (SMD = &#8722;0.21, 95% CI &#8722;0.83 to 0.42, <italic toggle="yes">p</italic> = 0.51; I<sup>2</sup> = 66.9%, <italic toggle="yes">p</italic> = 0.082) and those in treated patients (SMD = 0.19, 95% CI &#8722;0.22 to 0.59, <italic toggle="yes">p</italic> = 0.37; I<sup>2</sup> = 88.7%, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="antioxidants-12-01484-f008" ref-type="fig">Figure 8</xref>).</p><p>The low level of certainty for cross-sectional studies (rating 2, &#8853;&#8853;&#8861;&#8861;) was downgraded to extremely low (rating 0, &#8861;&#8861;&#8861;&#8861;) after considering the high and unexplained heterogeneity, the relatively high imprecision, and the presence of publication bias.</p></sec><sec id="sec3dot3-antioxidants-12-01484"><title>3.3. Arylesterase Activity</title><p>Ten studies including 14 study groups, all with a low risk of bias (<xref rid="app1-antioxidants-12-01484" ref-type="app">Supplementary Table S3</xref>), reported arylesterase activity in a total of 562 patients (mean age 34 years, 65% males) and 507 healthy controls (mean age 35 years, 59% males) [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>]. Five studies were conducted in Turkey [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>], two in Romania [<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>], two in Brazil [<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>], and one in Israel [<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>]. Ten study groups investigated patients receiving pharmacological treatment for schizophrenia [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>] and four untreated patients [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>]. Arylesterase activity was evaluated by using phenylacetate as a substrate in all studies [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>].</p><p>In forest plots, arylesterase activity was non-significantly different between control subjects and patients with schizophrenia (SMD = &#8722;0.08, 95% CI &#8722;0.39 to 0.23; <italic toggle="yes">p</italic> = 0.61; I<sup>2</sup> = 82.8%, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="antioxidants-12-01484-f009" ref-type="fig">Figure 9</xref>). A sensitivity analysis showed stability of the results, with pooled SMD values ranging between &#8722;0.16 and &#8722;0.02; <xref rid="antioxidants-12-01484-f010" ref-type="fig">Figure 10</xref>).</p><p>There was no publication bias with the Begg&#8217;s test (<italic toggle="yes">p</italic> = 0.66), the Egger&#8217;s test (<italic toggle="yes">p</italic> = 0.75), or the &#8220;trim-and-fill&#8221; method (<xref rid="antioxidants-12-01484-f011" ref-type="fig">Figure 11</xref>).</p><p>No significant associations were observed in meta-regression between the effect size and the proportion of males (t = &#8722;1.07, <italic toggle="yes">p</italic> = 0.31), the publication year (t = 0.46, <italic toggle="yes">p</italic> = 0.65), or the sample size (t = &#8722;0.02, <italic toggle="yes">p</italic> = 0.99). By contrast, we observed significant positive associations between the effect size and the patient/control age ratio (t = &#8722;3.36, <italic toggle="yes">p</italic> = 0.007; <xref rid="antioxidants-12-01484-f012" ref-type="fig">Figure 12</xref>A), the patient/control body mass index ratio (t = 3.52, <italic toggle="yes">p</italic> = 0.012; <xref rid="antioxidants-12-01484-f013" ref-type="fig">Figure 13</xref>A), and the patient/control HDL&#8211;cholesterol ratio (t = 4.39, <italic toggle="yes">p</italic> = 0.002; <xref rid="antioxidants-12-01484-f014" ref-type="fig">Figure 14</xref>A). Similar results were observed using the metacum analysis command (<xref rid="antioxidants-12-01484-f012" ref-type="fig">Figure 12</xref>B, <xref rid="antioxidants-12-01484-f013" ref-type="fig">Figure 13</xref>B and <xref rid="antioxidants-12-01484-f014" ref-type="fig">Figure 14</xref>B).</p><p>In the subgroup analysis, there were non-significant differences (<italic toggle="yes">p</italic> = 0.23) in SMD values between studies conducted in Turkey (SMD = &#8722;0.29, 95% CI &#8722;0.72 to 0.13, <italic toggle="yes">p</italic> = 0.18; I<sup>2</sup> = 81.0%, <italic toggle="yes">p</italic> &lt; 0.001) and those conducted in other countries (SMD = 0.15, 95% CI &#8722;0.33 to 0.62, <italic toggle="yes">p</italic> = 0.54; I<sup>2</sup> = 84.9%, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="antioxidants-12-01484-f015" ref-type="fig">Figure 15</xref>). By contrast, the pooled SMD was significantly lower in studies conducted in untreated patients (SMD = &#8722;0.48, 95% CI &#8722;0.73 to &#8722;0.24, <italic toggle="yes">p</italic> &lt; 0.001; I<sup>2</sup> = 0.0%, <italic toggle="yes">p</italic> = 0.77) but not in those conducted in treated patients (SMD = 0.07, 95% CI &#8722;0.32 to 0.47, <italic toggle="yes">p</italic> = 0.71; I<sup>2</sup> = 85.4%, <italic toggle="yes">p</italic> &lt; 0.001; <xref rid="antioxidants-12-01484-f016" ref-type="fig">Figure 16</xref>), with a virtually absent heterogeneity in the former subgroup.</p><p>The low level of certainty for cross-sectional studies (rating 2, &#8853;&#8853;&#8861;&#8861;) was downgraded to very low (rating 1, &#8853;&#8861;&#8861;&#8861;) after taking into account the relatively high imprecision (relatively large confidence intervals).</p></sec></sec><sec sec-type="discussion" id="sec4-antioxidants-12-01484"><title>4. Discussion</title><p>In our systematic review and meta-analysis, the enzymatic activity of paraoxonase and arylesterase, two essential components of circulating paraoxonase-1, were non-significantly different between patients with schizophrenia and healthy controls. However, in a meta-regression analysis we identified the presence of significant associations between the effect size of paraoxonase activity and patient/control age and HDL&#8211;cholesterol ratios, and between the effect size of arylesterase activity and patient/control age, body mass index, and HDL&#8211;cholesterol ratios. Furthermore, in a subgroup analysis the effect size of paraoxonase activity was significantly associated with the study country, whereas the effect size of arylesterase was significantly associated with pharmacological treatment for schizophrenia. In sensitivity analyses, the pooled SMD values of paraoxonase and arylesterase activity were not substantially influenced by individual studies, suggesting stability of the results of the meta-analysis.</p><p>The increasing evidence of a state of oxidative stress associated with schizophrenia has stimulated a significant body of research investigating the clinical significance of alterations in the redox state in this condition as well as other associated co-morbidities. In this context, studies have recently investigated the association between several biomarkers of oxidative stress, the duration of schizophrenia, and specific symptoms and psychopathological features of the disease, with contrasting results in terms of the direction of the observed associations [<xref rid="B9-antioxidants-12-01484" ref-type="bibr">9</xref>,<xref rid="B74-antioxidants-12-01484" ref-type="bibr">74</xref>]. Pending the results of additional investigations seeking to address this issue, the observed inconsistency in the available evidence could be related, at least in part, to the multiple biochemical and molecular pathways involved in redox homeostatic mechanisms and the complex analytical procedures required for the determination of biomarkers of oxidative stress in the blood and other biological matrices, with the potential for error [<xref rid="B75-antioxidants-12-01484" ref-type="bibr">75</xref>,<xref rid="B76-antioxidants-12-01484" ref-type="bibr">76</xref>]. Another factor that is likely to play an important role is represented by the interindividual variability in the clinical and demographic characteristics of the study participants [<xref rid="B9-antioxidants-12-01484" ref-type="bibr">9</xref>].</p><p>In terms of inter-individual variability in patient characteristics, there is good evidence that the redox state can be significantly influenced by age [<xref rid="B77-antioxidants-12-01484" ref-type="bibr">77</xref>], gender [<xref rid="B78-antioxidants-12-01484" ref-type="bibr">78</xref>], and several other sociodemographic and biochemical factors, particularly cigarette smoking, C-reactive protein concentrations, hyperglycaemia, nutrients, physical activity, and body mass index [<xref rid="B79-antioxidants-12-01484" ref-type="bibr">79</xref>,<xref rid="B80-antioxidants-12-01484" ref-type="bibr">80</xref>]. This complexity could explain, at least in part, some of the results of our meta-regression and subgroup analyses, particularly the significant negative associations between the SMD of paraoxonase/arylesterase activity and the patient/control age ratio and the significant positive associations between the SMD of paraoxonase/arylesterase and the patient/control HDL&#8211;cholesterol ratio. In other words, our analyses suggest that further studies are more likely to observe significant reductions in paraoxonase/arylesterase activity in subgroups of schizophrenic patients with older age and low HDL&#8211;cholesterol concentrations rather than older patients with high HDL&#8211;cholesterol concentrations and younger patients with low or high HDL&#8211;cholesterol concentrations. This hypothesis is also in line with the reported associations between schizophrenia and other conditions characterized by a pro-oxidative state, particularly atherosclerosis and cardiovascular disease, that are also more likely to affect older schizophrenic patients with relatively low HDL&#8211;cholesterol concentrations, given the established role of advancing age and low HDL&#8211;cholesterol as cardiovascular risk factors [<xref rid="B81-antioxidants-12-01484" ref-type="bibr">81</xref>,<xref rid="B82-antioxidants-12-01484" ref-type="bibr">82</xref>].</p><p>The presence of a strong association between schizophrenia and atherosclerotic cardiovascular disease has been highlighted in a systematic review and meta-analysis that included 38 studies, of which 29 were longitudinal, assessing a total of 1,591,106 patients with schizophrenia. In cross-sectional studies, schizophrenia was significantly associated with the presence of coronary heart disease (adjusted odds ratio, OR = 1.52, 95% CI 1.48 to 1.56, <italic toggle="yes">p</italic> &lt; 0.001), cerebrovascular disease (adjusted OR = 2.05, 95% CI 1.59 to 2.64, <italic toggle="yes">p</italic> &lt; 0.001), and congestive heart failure (adjusted OR = 1.60, 95% CI 1.06 to 2.40, <italic toggle="yes">p</italic> = 0.02). Similar results were observed in longitudinal studies where schizophrenia was significantly associated with incident cardiovascular disease (adjusted hazard ratio, HR = 1.95, 95% CI 1.41 to 2.70, <italic toggle="yes">p</italic> &lt; 0.001), incident coronary heart disease (adjusted HR = 1.59, 95% CI 1.08 to 2.35, <italic toggle="yes">p</italic> = 0.02), incident cerebrovascular disease (adjusted HR = 1.57, 1.09 to 2.25, <italic toggle="yes">p</italic> = 0.02), and incident congestive heart failure (unadjusted relative risk, RR = 1.80, 95% CI 1.15 to 2.79, <italic toggle="yes">p</italic> = 0.009) [<xref rid="B14-antioxidants-12-01484" ref-type="bibr">14</xref>]. A number of mechanisms have been suggested to account for the increased cardiovascular risk in patients with schizophrenia, including the high prevalence of smoking, unhealthy dietary patterns, and physical inactivity [<xref rid="B17-antioxidants-12-01484" ref-type="bibr">17</xref>,<xref rid="B83-antioxidants-12-01484" ref-type="bibr">83</xref>]. Studies have also reported a significant reduction in the concentrations of HDL&#8211;cholesterol, a cholesterol fraction that is critically linked with paraoxonase-1, in patients with schizophrenia [<xref rid="B84-antioxidants-12-01484" ref-type="bibr">84</xref>,<xref rid="B85-antioxidants-12-01484" ref-type="bibr">85</xref>,<xref rid="B86-antioxidants-12-01484" ref-type="bibr">86</xref>]. In one study, patients with acute-phase schizophrenia had significantly lower HDL concentrations compared to healthy subjects (43 &#177; 14 vs. 53 &#177; 13 mg/dL, <italic toggle="yes">p</italic> = 0.03). Interestingly, a significant increase in HDL&#8211;cholesterol was observed in patients who responded to three-week treatment with atypical antipsychotic drugs (+4 &#177; 8 mg/dL, <italic toggle="yes">p</italic> = 0.007) but not with conventional antipsychotics (+0.5 &#177; 14 mg/dL, <italic toggle="yes">p</italic> = 0.82) [<xref rid="B87-antioxidants-12-01484" ref-type="bibr">87</xref>]. The beneficial effects of some antipsychotic agents on HDL&#8211;cholesterol concentrations have also been reported in a systematic review and meta-analysis of 22 studies that investigated the effects of 10 different antipsychotics in 7073 patients compared to placebos in 2189 patients. Aripiprazole and brexpiprazole were the antipsychotic agents causing the greatest increase in HDL&#8211;cholesterol concentrations vs. placebo [<xref rid="B88-antioxidants-12-01484" ref-type="bibr">88</xref>]. Additional studies should investigate the presence of possible associations between paraoxonase/arylesterase activity, individual cardiovascular risk factors, and clinical cardiovascular endpoints (e.g., myocardial infarction, stroke, and congestive heart failure) in schizophrenia. These studies should also determine whether such associations are influenced by age, sex, ethnicity, specific disease subtypes, HDL&#8211;cholesterol concentrations, and treatment with specific antipsychotic drugs.</p><p>Another interesting observation in our subgroup analysis was the presence of significant reductions in arylesterase activity in studies of untreated patients but not in those of patients receiving pharmacological treatment for schizophrenia. Albeit hypothesis-generating, this finding suggests that treatment with antipsychotic drugs might increase arylesterase activity to levels that are comparable to those observed in healthy subjects. This would dilute the differences in arylesterase activity between treated patients and healthy controls. A systematic review and meta-analysis published in 2011 did not report any conclusive evidence regarding the effect of antipsychotic drugs on oxidative stress [<xref rid="B89-antioxidants-12-01484" ref-type="bibr">89</xref>]. However, a more recent systematic review has reported that olanzapine, paliperidone, risperidone, and haloperidol prevent oxidative stress-induced neurotoxicity in in vitro studies [<xref rid="B90-antioxidants-12-01484" ref-type="bibr">90</xref>]. Clearly, more research is warranted to investigate the effect of individual antipsychotic drugs on oxidative stress in patients with schizophrenia in studies that also include a range of genetic polymorphisms of paraoxonase as a potential modulating factor [<xref rid="B91-antioxidants-12-01484" ref-type="bibr">91</xref>,<xref rid="B92-antioxidants-12-01484" ref-type="bibr">92</xref>,<xref rid="B93-antioxidants-12-01484" ref-type="bibr">93</xref>,<xref rid="B94-antioxidants-12-01484" ref-type="bibr">94</xref>]. This issue is particularly relevant as there is good evidence that treatment with antipsychotic medications, particularly atypical antipsychotics, is also associated with weight gain, insulin resistance, diabetes, and dyslipidaemia in this patient group, with a consequent increase in the overall cardiovascular risk [<xref rid="B95-antioxidants-12-01484" ref-type="bibr">95</xref>,<xref rid="B96-antioxidants-12-01484" ref-type="bibr">96</xref>,<xref rid="B97-antioxidants-12-01484" ref-type="bibr">97</xref>]. At the same time, however, a large observational study in 62,250 patients with schizophrenia followed for 20 years has reported that antipsychotic treatment is associated with reduced all-cause mortality and cardiovascular mortality in schizophrenia, with an adjusted HR of 0.62 (95% CI 0.57 to 0.67) for cardiovascular mortality. Notably, even in the presence of significant variability, virtually all studied antipsychotic agents were associated with a reduced risk of cardiovascular mortality in this study, particularly quetiapine (HR = 0.51, 95% CI 0.43 to 0.61), aripiprazole (HR = 0.52, 95% CI 0.30 to 0.89), clozapine (HR = 0.55, 95% CI 0.46 to 0.64), and risperidone (HR = 0.64, 95% CI 0.56 to 0.73) [<xref rid="B98-antioxidants-12-01484" ref-type="bibr">98</xref>]. In another study, the duration of treatment with antipsychotics (including typical and atypical antipsychotics) was significantly associated with a reduced risk of cardiovascular events in patients with schizophrenia (adjusted OR = 0.95, 95% CI 0.91 to 0.99, <italic toggle="yes">p</italic> = 0.014) after adjusting for age, urea, creatinine, uric acid, thyroxine, leukocytes, body mass index, and diastolic blood pressure [<xref rid="B99-antioxidants-12-01484" ref-type="bibr">99</xref>]. Large, well-designed prospective studies are likely to shed light on the complex interplay between schizophrenia, oxidative stress assessed by measuring paraoxonase/arylesterase activity, antipsychotic drugs, and cardiovascular disease.</p><p>Strengths of our study are the combined assessment of paraoxonase and arylesterase enzymatic activity, essential components of paraoxonase-1, the comprehensive set of meta-regression and subgroup analyses, the rigorous assessment of the risk of bias and the certainty of evidence, and the stability of the results after sequentially removing individual studies in a sensitivity analysis. A significant limitation is that a significant proportion of studies was conducted in one country, Turkey, which limits the generalisability of the results to other patient populations, particularly European, North American, and Eastern Asian patients. This issue requires further research as studies conducted in USA and South Africa have reported the presence of significant ethnic-related differences in paraoxonase-1 [<xref rid="B100-antioxidants-12-01484" ref-type="bibr">100</xref>,<xref rid="B101-antioxidants-12-01484" ref-type="bibr">101</xref>,<xref rid="B102-antioxidants-12-01484" ref-type="bibr">102</xref>].</p></sec><sec sec-type="conclusions" id="sec5-antioxidants-12-01484"><title>5. Conclusions</title><p>Our study has shown the presence of non-significant differences in circulating paraoxonase-1, expressed as paraoxonase and arylesterase enzyme activity, between patients with schizophrenia and healthy controls. However, the results of meta-regression and subgroup analyses suggest that such differences may be significant in subgroups of patients with schizophrenia, particularly older patients with relatively low HDL&#8211;cholesterol concentrations. Further studies should address this issue by investigating paraoxonase-1 and the possible effects of antipsychotic drugs and other antioxidant strategies on disease progression and cardiovascular risk in these subgroups and consider the modulating effect of genetic polymorphisms of paraoxonase-1 and ethnic differences.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-antioxidants-12-01484"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/antiox12081484/s1">https://www.mdpi.com/article/10.3390/antiox12081484/s1</uri>, Table S1: PRISMA 2020 for abstracts checklist; Table S2: PRISMA 2020 checklist; Table S3: The Joanna Briggs Institute critical appraisal checklist.</p><supplementary-material id="antioxidants-12-01484-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="antioxidants-12-01484-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>A.Z., S.S. and A.A.M. conceived the study, conducted the literature search, and analyzed the data. A.A.M. wrote the first draft. A.Z., S.S. and A.A.M. reviewed further drafts and the final version. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The relevant data are available from A.Z. upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antioxidants-12-01484"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upthegrove</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khandaker</surname><given-names>G.M.</given-names></name></person-group><article-title>Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia</article-title><source>Curr. Top. Behav. Neurosci.</source><year>2020</year><volume>44</volume><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/7854_2018_88</pub-id><pub-id pub-id-type="pmid">31115797</pub-id></element-citation></ref><ref id="B2-antioxidants-12-01484"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Katshu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liddle</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Upthegrove</surname><given-names>R.</given-names></name></person-group><article-title>Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders</article-title><source>Front. Psychiatry</source><year>2021</year><volume>12</volume><fpage>703452</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2021.703452</pub-id><pub-id pub-id-type="pmid">34366935</pub-id><pub-id pub-id-type="pmcid">PMC8339376</pub-id></element-citation></ref><ref id="B3-antioxidants-12-01484"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rambaud</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaumette</surname><given-names>B.</given-names></name></person-group><article-title>Oxidative Stress and Emergence of Psychosis</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>1870</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11101870</pub-id><pub-id pub-id-type="pmid">36290593</pub-id><pub-id pub-id-type="pmcid">PMC9598314</pub-id></element-citation></ref><ref id="B4-antioxidants-12-01484"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Samkaria</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ingole</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goel</surname><given-names>A.</given-names></name></person-group><article-title>Schizophrenia, Bipolar and Major Depressive Disorders: Overview of Clinical Features, Neurotransmitter Alterations, Pharmacological Interventions, and Impact of Oxidative Stress in the Disease Process</article-title><source>ACS Chem. Neurosci.</source><year>2022</year><volume>13</volume><fpage>2784</fpage><lpage>2802</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.2c00420</pub-id><pub-id pub-id-type="pmid">36125113</pub-id></element-citation></ref><ref id="B5-antioxidants-12-01484"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisar</surname><given-names>Z.</given-names></name></person-group><article-title>Biological hypotheses, risk factors, and biomarkers of schizophrenia</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><year>2023</year><volume>120</volume><fpage>110626</fpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2022.110626</pub-id><pub-id pub-id-type="pmid">36055561</pub-id></element-citation></ref><ref id="B6-antioxidants-12-01484"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallee</surname><given-names>A.</given-names></name></person-group><article-title>Neuroinflammation in Schizophrenia: The Key Role of the WNT/beta-Catenin Pathway</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>2810</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23052810</pub-id><pub-id pub-id-type="pmid">35269952</pub-id><pub-id pub-id-type="pmcid">PMC8910888</pub-id></element-citation></ref><ref id="B7-antioxidants-12-01484"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abruzzo</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Panisi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marini</surname><given-names>M.</given-names></name></person-group><article-title>The Alteration of Chloride Homeostasis/GABAergic Signaling in Brain Disorders: Could Oxidative Stress Play a Role?</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><elocation-id>1316</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10081316</pub-id><pub-id pub-id-type="pmid">34439564</pub-id><pub-id pub-id-type="pmcid">PMC8389245</pub-id></element-citation></ref><ref id="B8-antioxidants-12-01484"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Walder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marx</surname><given-names>W.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>B.K.</given-names></name></person-group><article-title>Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry</article-title><source>Mol. Neurobiol.</source><year>2021</year><volume>58</volume><fpage>2158</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02212-w</pub-id><pub-id pub-id-type="pmid">33411248</pub-id></element-citation></ref><ref id="B9-antioxidants-12-01484"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juchnowicz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dzikowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rog</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waszkiewicz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zalewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maciejczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karakula-Juchnowicz</surname><given-names>H.</given-names></name></person-group><article-title>Oxidative Stress Biomarkers as a Predictor of Stage Illness and Clinical Course of Schizophrenia</article-title><source>Front. Psychiatry</source><year>2021</year><volume>12</volume><fpage>728986</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2021.728986</pub-id><pub-id pub-id-type="pmid">34867519</pub-id><pub-id pub-id-type="pmcid">PMC8636114</pub-id></element-citation></ref><ref id="B10-antioxidants-12-01484"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lafeuille</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fastenau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Panish</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>P.</given-names></name></person-group><article-title>Burden of schizophrenia on selected comorbidity costs</article-title><source>Expert Rev. Pharm. Outcomes Res.</source><year>2014</year><volume>14</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1586/14737167.2014.894463</pub-id><pub-id pub-id-type="pmid">24593801</pub-id></element-citation></ref><ref id="B11-antioxidants-12-01484"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okahisa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>N.</given-names></name></person-group><article-title>Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2021</year><volume>24</volume><fpage>367</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyaa097</pub-id><pub-id pub-id-type="pmid">33315097</pub-id><pub-id pub-id-type="pmcid">PMC8130204</pub-id></element-citation></ref><ref id="B12-antioxidants-12-01484"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Smoller</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.H.</given-names></name></person-group><article-title>Large-scale real-world data analysis identifies comorbidity patterns in schizophrenia</article-title><source>Transl. Psychiatry</source><year>2022</year><volume>12</volume><fpage>154</fpage><pub-id pub-id-type="doi">10.1038/s41398-022-01916-y</pub-id><pub-id pub-id-type="pmid">35410453</pub-id><pub-id pub-id-type="pmcid">PMC9001711</pub-id></element-citation></ref><ref id="B13-antioxidants-12-01484"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanihara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>A.</given-names></name></person-group><article-title>Recent findings on subjective well-being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review</article-title><source>Neuropsychopharmacol. Rep.</source><year>2022</year><volume>42</volume><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1002/npr2.12286</pub-id><pub-id pub-id-type="pmid">35916310</pub-id><pub-id pub-id-type="pmcid">PMC9773775</pub-id></element-citation></ref><ref id="B14-antioxidants-12-01484"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Solmi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veronese</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bortolato</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rosson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santonastaso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thapa-Chhetri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gallicchio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Collantoni</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls</article-title><source>World Psychiatry</source><year>2017</year><volume>16</volume><fpage>163</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1002/wps.20420</pub-id><pub-id pub-id-type="pmid">28498599</pub-id><pub-id pub-id-type="pmcid">PMC5428179</pub-id></element-citation></ref><ref id="B15-antioxidants-12-01484"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennekens</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Hennekens</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Hollar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>D.E.</given-names></name></person-group><article-title>Schizophrenia and increased risks of cardiovascular disease</article-title><source>Am. Heart J.</source><year>2005</year><volume>150</volume><fpage>1115</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.007</pub-id><pub-id pub-id-type="pmid">16338246</pub-id></element-citation></ref><ref id="B16-antioxidants-12-01484"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossom</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Hooker</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Crain</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Sperl-Hillen</surname><given-names>J.M.</given-names></name></person-group><article-title>Cardiovascular Risk for Patients with and without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder</article-title><source>J. Am. Heart Assoc.</source><year>2022</year><volume>11</volume><fpage>e021444</fpage><pub-id pub-id-type="doi">10.1161/JAHA.121.021444</pub-id><pub-id pub-id-type="pmid">35261265</pub-id><pub-id pub-id-type="pmcid">PMC9075298</pub-id></element-citation></ref><ref id="B17-antioxidants-12-01484"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Banner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Cardiovascular disease in patients with severe mental illness</article-title><source>Nat. Rev. Cardiol.</source><year>2021</year><volume>18</volume><fpage>136</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-00463-7</pub-id><pub-id pub-id-type="pmid">33128044</pub-id></element-citation></ref><ref id="B18-antioxidants-12-01484"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marche</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bannay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baillot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dauriac-Le Masson</surname><given-names>V.</given-names></name><name name-style="western"><surname>Leveque</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Laprevote</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schwan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dobre</surname><given-names>D.</given-names></name></person-group><article-title>Prevalence of severe cardiovascular disease in patients with schizophrenia</article-title><source>Encephale</source><year>2022</year><volume>48</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.encep.2021.02.008</pub-id><pub-id pub-id-type="pmid">34024498</pub-id></element-citation></ref><ref id="B19-antioxidants-12-01484"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraguas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Diaz-Caneja</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ayora</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hernandez-Alvarez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rodriguez-Quiroga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Recio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leza</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Arango</surname><given-names>C.</given-names></name></person-group><article-title>Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis</article-title><source>Schizophr. Bull.</source><year>2019</year><volume>45</volume><fpage>742</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1093/schbul/sby125</pub-id><pub-id pub-id-type="pmid">30169868</pub-id><pub-id pub-id-type="pmcid">PMC6581144</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC11823467"/></element-citation></ref><ref id="B20-antioxidants-12-01484"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Lakkakula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kadir</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeffree</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lakkakula</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.V.</given-names></name></person-group><article-title>Biomarkers of Oxidative Stress Tethered to Cardiovascular Diseases</article-title><source>Oxidative Med. Cell. Longev.</source><year>2022</year><volume>2022</volume><fpage>9154295</fpage><pub-id pub-id-type="doi">10.1155/2022/9154295</pub-id><pub-id pub-id-type="pmcid">PMC9249518</pub-id><pub-id pub-id-type="pmid">35783193</pub-id></element-citation></ref><ref id="B21-antioxidants-12-01484"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caruso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grasso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fidilio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tascedda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Drago</surname><given-names>F.</given-names></name><name name-style="western"><surname>Caraci</surname><given-names>F.</given-names></name></person-group><article-title>Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>457</elocation-id><pub-id pub-id-type="doi">10.3390/ph13120457</pub-id><pub-id pub-id-type="pmid">33322693</pub-id><pub-id pub-id-type="pmcid">PMC7764768</pub-id></element-citation></ref><ref id="B22-antioxidants-12-01484"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietrich-Muszalska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolodziejczyk-Czepas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>P.</given-names></name></person-group><article-title>Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2021</year><volume>17</volume><fpage>555</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.2147/NDT.S283395</pub-id><pub-id pub-id-type="pmid">33628026</pub-id><pub-id pub-id-type="pmcid">PMC7898201</pub-id></element-citation></ref><ref id="B23-antioxidants-12-01484"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name></person-group><article-title>A Systematic Review and Meta-Analysis of the Effect of Statins on Glutathione Peroxidase, Superoxide Dismutase, and Catalase</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><elocation-id>1841</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10111841</pub-id><pub-id pub-id-type="pmid">34829712</pub-id><pub-id pub-id-type="pmcid">PMC8614838</pub-id></element-citation></ref><ref id="B24-antioxidants-12-01484"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paliogiannis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Usai</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name></person-group><article-title>Effect of statin treatment on circulating malondialdehyde concentrations: A systematic review and meta-analysis</article-title><source>Ther. Adv. Chronic Dis.</source><year>2019</year><volume>10</volume><fpage>2040622319862714</fpage><pub-id pub-id-type="doi">10.1177/2040622319862714</pub-id><pub-id pub-id-type="pmid">31367297</pub-id><pub-id pub-id-type="pmcid">PMC6643183</pub-id></element-citation></ref><ref id="B25-antioxidants-12-01484"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sotgia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sanna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satta</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name></person-group><article-title>Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: Relationship with oxidative stress improvement</article-title><source>Nutr. Metab. Cardiovasc. Dis.</source><year>2015</year><volume>25</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2014.11.004</pub-id><pub-id pub-id-type="pmid">25534866</pub-id></element-citation></ref><ref id="B26-antioxidants-12-01484"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackness</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mackness</surname><given-names>B.</given-names></name></person-group><article-title>Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles</article-title><source>Gene</source><year>2015</year><volume>567</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2015.04.088</pub-id><pub-id pub-id-type="pmid">25965560</pub-id><pub-id pub-id-type="pmcid">PMC4458450</pub-id></element-citation></ref><ref id="B27-antioxidants-12-01484"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackness</surname><given-names>B.</given-names></name><name name-style="western"><surname>Durrington</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Mackness</surname><given-names>M.I.</given-names></name></person-group><article-title>Human serum paraoxonase</article-title><source>Gen. Pharmacol. Vasc. Syst.</source><year>1998</year><volume>31</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/S0306-3623(98)00028-7</pub-id><pub-id pub-id-type="pmid">9703197</pub-id></element-citation></ref><ref id="B28-antioxidants-12-01484"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name></person-group><article-title>HDL Structure</article-title><source>Adv. Exp. Med. Biol.</source><year>2022</year><volume>1377</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/978-981-19-1592-5_1</pub-id><pub-id pub-id-type="pmid">35575917</pub-id></element-citation></ref><ref id="B29-antioxidants-12-01484"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aviram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosenblat</surname><given-names>M.</given-names></name></person-group><article-title>Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development</article-title><source>Free. Radic. Biol. Med.</source><year>2004</year><volume>37</volume><fpage>1304</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.06.030</pub-id><pub-id pub-id-type="pmid">15454271</pub-id></element-citation></ref><ref id="B30-antioxidants-12-01484"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Wadleigh</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Grijalva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gangopadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Lusis</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Navab</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fogelman</surname><given-names>A.M.</given-names></name></person-group><article-title>Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2001</year><volume>21</volume><fpage>542</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.21.4.542</pub-id><pub-id pub-id-type="pmid">11304470</pub-id></element-citation></ref><ref id="B31-antioxidants-12-01484"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Substrates for Paraoxonase</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.2174/1381612824666171213102310</pub-id><pub-id pub-id-type="pmid">29237378</pub-id></element-citation></ref><ref id="B32-antioxidants-12-01484"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldridge</surname><given-names>W.N.</given-names></name></person-group><article-title>Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera</article-title><source>Biochem. J.</source><year>1953</year><volume>53</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1042/bj0530117</pub-id><pub-id pub-id-type="pmid">13032042</pub-id><pub-id pub-id-type="pmcid">PMC1198111</pub-id></element-citation></ref><ref id="B33-antioxidants-12-01484"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakubowski</surname><given-names>H.</given-names></name></person-group><article-title>Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>3957</fpage><lpage>3962</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.6.3957</pub-id><pub-id pub-id-type="pmid">10660550</pub-id></element-citation></ref><ref id="B34-antioxidants-12-01484"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthukrishnan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shete</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Sanan</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Vyas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oottikkal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Magliery</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Hadad</surname><given-names>C.M.</given-names></name></person-group><article-title>Mechanistic Insights into the Hydrolysis of Organophosphorus Compounds by Paraoxonase-1: Exploring the Limits of Substrate Tolerance in a Promiscuous Enzyme</article-title><source>J. Phys. Org. Chem.</source><year>2012</year><volume>25</volume><fpage>1247</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1002/poc.3002</pub-id><pub-id pub-id-type="pmid">23946555</pub-id><pub-id pub-id-type="pmcid">PMC3740977</pub-id></element-citation></ref><ref id="B35-antioxidants-12-01484"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fois</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sotgia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pintus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pirina</surname><given-names>P.</given-names></name></person-group><article-title>Plasma protein thiols: An early marker of oxidative stress in asthma and chronic obstructive pulmonary disease</article-title><source>Eur. J. Clin. Investig.</source><year>2016</year><volume>46</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1111/eci.12582</pub-id><pub-id pub-id-type="pmid">26681451</pub-id></element-citation></ref><ref id="B36-antioxidants-12-01484"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fois</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sotgia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sotgiu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Pirina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name></person-group><article-title>Arginines Plasma Concentration and Oxidative Stress in Mild to Moderate COPD</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0160237</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160237</pub-id><pub-id pub-id-type="pmid">27479314</pub-id><pub-id pub-id-type="pmcid">PMC4968788</pub-id></element-citation></ref><ref id="B37-antioxidants-12-01484"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erre</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Bassu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giordo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pintus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name></person-group><article-title>Association between Paraoxonase/Arylesterase Activity of Serum PON-1 Enzyme and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>2317</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11122317</pub-id><pub-id pub-id-type="pmid">36552525</pub-id><pub-id pub-id-type="pmcid">PMC9774899</pub-id></element-citation></ref><ref id="B38-antioxidants-12-01484"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pau</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pintus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fois</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Pirina</surname><given-names>P.</given-names></name></person-group><article-title>Paraoxonase-1 Concentrations in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>766</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11040766</pub-id><pub-id pub-id-type="pmid">35453451</pub-id><pub-id pub-id-type="pmcid">PMC9028830</pub-id></element-citation></ref><ref id="B39-antioxidants-12-01484"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Argiolas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pirina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fois</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name></person-group><article-title>A systematic review and meta-analysis of paraoxonase-1 activity in asthma</article-title><source>Clin. Exp. Med.</source><year>2022</year><pub-id pub-id-type="doi">10.1007/s10238-022-00930-0</pub-id><pub-id pub-id-type="pmcid">PMC10390600</pub-id><pub-id pub-id-type="pmid">36344783</pub-id></element-citation></ref><ref id="B40-antioxidants-12-01484"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Satta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Argiolas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name></person-group><article-title>Paraoxonase and arylesterase activity of serum PON-1 enzyme in psoriatic patients: A systematic review and meta-analysis</article-title><source>Clin. Exp. Med.</source><year>2023</year><volume>23</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1007/s10238-022-00818-z</pub-id><pub-id pub-id-type="pmid">35313365</pub-id><pub-id pub-id-type="pmcid">PMC10224865</pub-id></element-citation></ref><ref id="B41-antioxidants-12-01484"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sotgia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Floris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farina</surname><given-names>G.</given-names></name><name name-style="western"><surname>Passiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Erre</surname><given-names>G.L.</given-names></name></person-group><article-title>Oxidative Stress Biomarkers and Peripheral Endothelial Dysfunction in Rheumatoid Arthritis: A Monocentric Cross-Sectional Case-Control Study</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>3855</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25173855</pub-id><pub-id pub-id-type="pmid">32854225</pub-id><pub-id pub-id-type="pmcid">PMC7504109</pub-id></element-citation></ref><ref id="B42-antioxidants-12-01484"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durrington</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soran</surname><given-names>H.</given-names></name></person-group><article-title>Paraoxonase 1 and atherosclerosis</article-title><source>Front. Cardiovasc. Med.</source><year>2023</year><volume>10</volume><fpage>1065967</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1065967</pub-id><pub-id pub-id-type="pmid">36873390</pub-id><pub-id pub-id-type="pmcid">PMC9977831</pub-id></element-citation></ref><ref id="B43-antioxidants-12-01484"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navab</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anantharamaiah</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Van Lenten</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Ansell</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Fogelman</surname><given-names>A.M.</given-names></name></person-group><article-title>Mechanisms of disease: Proatherogenic HDL&#8212;An evolving field</article-title><source>Nat. Clin. Pract. Endocrinol. Metab.</source><year>2006</year><volume>2</volume><fpage>504</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/ncpendmet0245</pub-id><pub-id pub-id-type="pmid">16957764</pub-id></element-citation></ref><ref id="B44-antioxidants-12-01484"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Feig</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Hewing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hazen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.D.</given-names></name></person-group><article-title>High-density lipoprotein function, dysfunction, and reverse cholesterol transport</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2012</year><volume>32</volume><fpage>2813</fpage><lpage>2820</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300133</pub-id><pub-id pub-id-type="pmid">23152494</pub-id><pub-id pub-id-type="pmcid">PMC3501261</pub-id></element-citation></ref><ref id="B45-antioxidants-12-01484"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Catapano</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Norata</surname><given-names>G.D.</given-names></name></person-group><article-title>Biological Consequences of Dysfunctional HDL</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>1644</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.2174/0929867325666180530110543</pub-id><pub-id pub-id-type="pmid">29848265</pub-id></element-citation></ref><ref id="B46-antioxidants-12-01484"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Napolitano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fasciolo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tomajoli</surname><given-names>M.T.M.</given-names></name><name name-style="western"><surname>Carlucci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ascione</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>A.</given-names></name></person-group><article-title>Effects of superoxide anion attack on the lipoprotein HDL</article-title><source>Mol. Cell. Biochem.</source><year>2023</year><volume>478</volume><fpage>1059</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1007/s11010-022-04563-5</pub-id><pub-id pub-id-type="pmid">36219354</pub-id><pub-id pub-id-type="pmcid">PMC10126046</pub-id></element-citation></ref><ref id="B47-antioxidants-12-01484"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunutsor</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>James</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Dullaart</surname><given-names>R.P.</given-names></name></person-group><article-title>Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies</article-title><source>Atherosclerosis</source><year>2016</year><volume>245</volume><fpage>143</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.12.021</pub-id><pub-id pub-id-type="pmid">26724525</pub-id></element-citation></ref><ref id="B48-antioxidants-12-01484"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Moola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munn</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tufanaru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aromataris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sears</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sfetcu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Currie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mattis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lisy</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Systematic reviews of etiology and risk</article-title><source>Joanna Briggs Institute Reviewer&#8217;s Manual</source><person-group person-group-type="editor"><name name-style="western"><surname>Aromataris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Munn</surname><given-names>Z.</given-names></name></person-group><publisher-name>Johanna Briggs Institute</publisher-name><publisher-loc>Adelaide, Australia</publisher-loc><year>2017</year></element-citation></ref><ref id="B49-antioxidants-12-01484"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>Statistical Power Analysis</article-title><source>Curr. Dir. Psychol. Sci.</source><year>1992</year><volume>1</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/1467-8721.ep10768783</pub-id></element-citation></ref><ref id="B50-antioxidants-12-01484"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balshem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Helfand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schunemann</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Oxman</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kunz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brozek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vist</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Falck-Ytter</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meerpohl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>S.</given-names></name><etal/></person-group><article-title>GRADE guidelines: 3. Rating the quality of evidence</article-title><source>J. Clin. Epidemiol.</source><year>2011</year><volume>64</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2010.07.015</pub-id><pub-id pub-id-type="pmid">21208779</pub-id></element-citation></ref><ref id="B51-antioxidants-12-01484"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation></ref><ref id="B52-antioxidants-12-01484"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>T.</given-names></name></person-group><article-title>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</article-title><source>BMC Med. Res. Methodol.</source><year>2014</year><volume>14</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-14-135</pub-id><pub-id pub-id-type="pmid">25524443</pub-id><pub-id pub-id-type="pmcid">PMC4383202</pub-id></element-citation></ref><ref id="B53-antioxidants-12-01484"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hozo</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Djulbegovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hozo</surname><given-names>I.</given-names></name></person-group><article-title>Estimating the mean and variance from the median, range, and the size of a sample</article-title><source>BMC Med. Res. Methodol.</source><year>2005</year><volume>5</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-5-13</pub-id><pub-id pub-id-type="pmid">15840177</pub-id><pub-id pub-id-type="pmcid">PMC1097734</pub-id></element-citation></ref><ref id="B54-antioxidants-12-01484"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Copas</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Burdett</surname><given-names>S.</given-names></name></person-group><article-title>Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics</article-title><source>BMC Med. Res. Methodol.</source><year>2011</year><volume>11</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-11-41</pub-id><pub-id pub-id-type="pmid">21473747</pub-id><pub-id pub-id-type="pmcid">PMC3102034</pub-id></element-citation></ref><ref id="B55-antioxidants-12-01484"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>S.G.</given-names></name></person-group><article-title>Quantifying heterogeneity in a meta-analysis</article-title><source>Stat. Med.</source><year>2002</year><volume>21</volume><fpage>1539</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1002/sim.1186</pub-id><pub-id pub-id-type="pmid">12111919</pub-id></element-citation></ref><ref id="B56-antioxidants-12-01484"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>D.G.</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id></element-citation></ref><ref id="B57-antioxidants-12-01484"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tobias</surname><given-names>A.</given-names></name></person-group><article-title>Assessing the influence of a single study in the meta-analysis estimate</article-title><source>Stata Tech. Bull.</source><year>1999</year><volume>47</volume><fpage>15</fpage><lpage>17</lpage></element-citation></ref><ref id="B58-antioxidants-12-01484"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Begg</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Mazumdar</surname><given-names>M.</given-names></name></person-group><article-title>Operating characteristics of a rank correlation test for publication bias</article-title><source>Biometrics</source><year>1994</year><volume>50</volume><fpage>1088</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.2307/2533446</pub-id><pub-id pub-id-type="pmid">7786990</pub-id></element-citation></ref><ref id="B59-antioxidants-12-01484"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M.</given-names></name></person-group><article-title>Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis</article-title><source>J. Clin. Epidemiol.</source><year>2001</year><volume>54</volume><fpage>1046</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(01)00377-8</pub-id><pub-id pub-id-type="pmid">11576817</pub-id></element-citation></ref><ref id="B60-antioxidants-12-01484"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duval</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tweedie</surname><given-names>R.</given-names></name></person-group><article-title>Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title><source>Biometrics</source><year>2000</year><volume>56</volume><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1111/j.0006-341X.2000.00455.x</pub-id><pub-id pub-id-type="pmid">10877304</pub-id></element-citation></ref><ref id="B61-antioxidants-12-01484"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarandol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akkaya</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ocak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eroz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sarandol</surname><given-names>E.</given-names></name></person-group><article-title>Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment</article-title><source>J. Psychopharmacol.</source><year>2007</year><volume>21</volume><fpage>857</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1177/0269881107077609</pub-id><pub-id pub-id-type="pmid">17715203</pub-id></element-citation></ref><ref id="B62-antioxidants-12-01484"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yegin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ay</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aydin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yargici</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>N.</given-names></name></person-group><article-title>Increased Oxidant Stress and Inflammation in Patients with Chronic Schizophrenia</article-title><source>Int. J. Clin. Med.</source><year>2012</year><volume>3</volume><fpage>368</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.4236/ijcm.2012.35070</pub-id></element-citation></ref><ref id="B63-antioxidants-12-01484"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unsal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albayrak</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Albayrak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kuloglu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group><article-title>Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2013</year><volume>9</volume><fpage>1545</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.2147/NDT.S52463</pub-id><pub-id pub-id-type="pmid">24143103</pub-id><pub-id pub-id-type="pmcid">PMC3798239</pub-id></element-citation></ref><ref id="B64-antioxidants-12-01484"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piriu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Delia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Iosif</surname><given-names>L.</given-names></name><name name-style="western"><surname>Atanasiu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stoian</surname><given-names>I.</given-names></name></person-group><article-title>A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><fpage>4703</fpage><lpage>4710</lpage><pub-id pub-id-type="doi">10.1007/s00213-014-3624-0</pub-id><pub-id pub-id-type="pmid">24871701</pub-id><pub-id pub-id-type="pmcid">PMC4231214</pub-id></element-citation></ref><ref id="B65-antioxidants-12-01484"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mabrouk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mechria</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mechri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Neffati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Douki</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gaha</surname><given-names>L.</given-names></name><name name-style="western"><surname>Najjar</surname><given-names>M.F.</given-names></name></person-group><article-title>Paraoxonase 1 activity and lipid profile in schizophrenic patients</article-title><source>Asian J. Psychiatry</source><year>2014</year><volume>9</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ajp.2013.12.019</pub-id><pub-id pub-id-type="pmid">24813034</pub-id></element-citation></ref><ref id="B66-antioxidants-12-01484"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinholi</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Noto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonifacio</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Brietzke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Gadelha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Belangero</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Bressan</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naive first episode psychosis</article-title><source>Schizophr. Res.</source><year>2015</year><volume>166</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2015.06.009</pub-id><pub-id pub-id-type="pmid">26123170</pub-id></element-citation></ref><ref id="B67-antioxidants-12-01484"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussein</surname><given-names>O.</given-names></name><name name-style="western"><surname>Izikson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bathish</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dabur</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zidan</surname><given-names>J.</given-names></name></person-group><article-title>Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy</article-title><source>J. Psychopharmacol.</source><year>2015</year><volume>29</volume><fpage>1262</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1177/0269881115598320</pub-id><pub-id pub-id-type="pmid">26253619</pub-id></element-citation></ref><ref id="B68-antioxidants-12-01484"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarandol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sarandol</surname><given-names>E.</given-names></name><name name-style="western"><surname>Acikgoz</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Eker</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Akkaya</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dirican</surname><given-names>M.</given-names></name></person-group><article-title>First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment</article-title><source>Psychiatry Clin. Neurosci.</source><year>2015</year><volume>69</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1111/pcn.12333</pub-id><pub-id pub-id-type="pmid">26172069</pub-id></element-citation></ref><ref id="B69-antioxidants-12-01484"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Camkurt</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bulut</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demir</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ibiloglu</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Atli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sir</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment</article-title><source>Clin. Psychopharmacol. Neurosci.</source><year>2016</year><volume>14</volume><fpage>345</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.9758/cpn.2016.14.4.345</pub-id><pub-id pub-id-type="pmid">27776386</pub-id><pub-id pub-id-type="pmcid">PMC5083945</pub-id></element-citation></ref><ref id="B70-antioxidants-12-01484"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulaksizoglu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kulaksizoglu</surname><given-names>S.</given-names></name></person-group><article-title>Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2016</year><volume>12</volume><fpage>1999</fpage><lpage>2005</lpage><pub-id pub-id-type="doi">10.2147/NDT.S110484</pub-id><pub-id pub-id-type="pmid">27574431</pub-id><pub-id pub-id-type="pmcid">PMC4991539</pub-id></element-citation></ref><ref id="B71-antioxidants-12-01484"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atagun</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Tunc</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alisik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Erel</surname><given-names>O.</given-names></name></person-group><article-title>Phenotypic Variants of Paraoxonase Q192R in Bipolar Disorder, Depression and Schizophrenia</article-title><source>Turk. J. Psychiatry</source><year>2017</year><volume>29</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.5080/u21611</pub-id><pub-id pub-id-type="pmid">30215835</pub-id></element-citation></ref><ref id="B72-antioxidants-12-01484"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boll</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Noto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonifacio</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bortolasci</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Gadelha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bressan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.G.</given-names></name></person-group><article-title>Oxidative and nitrosative stress biomarkers in chronic schizophrenia</article-title><source>Psychiatry Res.</source><year>2017</year><volume>253</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2017.03.038</pub-id><pub-id pub-id-type="pmid">28346888</pub-id></element-citation></ref><ref id="B73-antioxidants-12-01484"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paval</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nemes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rusu</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Dronca</surname><given-names>E.</given-names></name></person-group><article-title>Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics</article-title><source>Clin. Psychopharmacol. Neurosci.</source><year>2018</year><volume>16</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.9758/cpn.2018.16.1.32</pub-id><pub-id pub-id-type="pmid">29397664</pub-id><pub-id pub-id-type="pmcid">PMC5810443</pub-id></element-citation></ref><ref id="B74-antioxidants-12-01484"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solberg</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Refsum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Andreassen</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Bentsen</surname><given-names>H.</given-names></name></person-group><article-title>A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia</article-title><source>Acta Neuropsychiatr.</source><year>2019</year><volume>31</volume><fpage>202</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1017/neu.2019.14</pub-id><pub-id pub-id-type="pmid">31178002</pub-id></element-citation></ref><ref id="B75-antioxidants-12-01484"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frijhoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Winyard</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Zarkovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Stocker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Oettrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruskovska</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Clinical Relevance of Biomarkers of Oxidative Stress</article-title><source>Antioxid. Redox Signal.</source><year>2015</year><volume>23</volume><fpage>1144</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1089/ars.2015.6317</pub-id><pub-id pub-id-type="pmid">26415143</pub-id><pub-id pub-id-type="pmcid">PMC4657513</pub-id></element-citation></ref><ref id="B76-antioxidants-12-01484"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrocco</surname><given-names>I.</given-names></name><name name-style="western"><surname>Altieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peluso</surname><given-names>I.</given-names></name></person-group><article-title>Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans</article-title><source>Oxidative Med. Cell. Longev.</source><year>2017</year><volume>2017</volume><fpage>6501046</fpage><pub-id pub-id-type="doi">10.1155/2017/6501046</pub-id><pub-id pub-id-type="pmid">28698768</pub-id><pub-id pub-id-type="pmcid">PMC5494111</pub-id></element-citation></ref><ref id="B77-antioxidants-12-01484"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohal</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>W.C.</given-names></name></person-group><article-title>The redox stress hypothesis of aging</article-title><source>Free. Radic. Biol. Med.</source><year>2012</year><volume>52</volume><fpage>539</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.10.445</pub-id><pub-id pub-id-type="pmid">22080087</pub-id><pub-id pub-id-type="pmcid">PMC3267846</pub-id></element-citation></ref><ref id="B78-antioxidants-12-01484"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kander</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Gender difference in oxidative stress: A new look at the mechanisms for cardiovascular diseases</article-title><source>J. Cell. Mol. Med.</source><year>2017</year><volume>21</volume><fpage>1024</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13038</pub-id><pub-id pub-id-type="pmid">27957792</pub-id><pub-id pub-id-type="pmcid">PMC5387169</pub-id></element-citation></ref><ref id="B79-antioxidants-12-01484"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grattagliano</surname><given-names>I.</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>Portincasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moschetta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palasciano</surname><given-names>G.</given-names></name></person-group><article-title>Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis</article-title><source>J. Nutr. Biochem.</source><year>2008</year><volume>19</volume><fpage>491</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2007.06.011</pub-id><pub-id pub-id-type="pmid">17855068</pub-id></element-citation></ref><ref id="B80-antioxidants-12-01484"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Norkus</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Hudes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L.</given-names></name></person-group><article-title>Factors associated with oxidative stress in human populations</article-title><source>Am. J. Epidemiol.</source><year>2002</year><volume>156</volume><fpage>274</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1093/aje/kwf029</pub-id><pub-id pub-id-type="pmid">12142263</pub-id></element-citation></ref><ref id="B81-antioxidants-12-01484"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weverling-Rijnsburger</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Jonkers</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>van Exel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gussekloo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Westendorp</surname><given-names>R.G.</given-names></name></person-group><article-title>High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age</article-title><source>Arch. Intern. Med.</source><year>2003</year><volume>163</volume><fpage>1549</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1001/archinte.163.13.1549</pub-id><pub-id pub-id-type="pmid">12860577</pub-id></element-citation></ref><ref id="B82-antioxidants-12-01484"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Thao</surname><given-names>L.T.P.</given-names></name><name name-style="western"><surname>Callander</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>E.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Donnan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Poppe</surname><given-names>K.K.</given-names></name><etal/></person-group><article-title>Cardiovascular risk prediction in healthy older people</article-title><source>Geroscience</source><year>2022</year><volume>44</volume><fpage>403</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1007/s11357-021-00486-z</pub-id><pub-id pub-id-type="pmid">34762275</pub-id><pub-id pub-id-type="pmcid">PMC8810999</pub-id></element-citation></ref><ref id="B83-antioxidants-12-01484"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Velakoulis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pantelis</surname><given-names>C.</given-names></name></person-group><article-title>Medical comorbidity in schizophrenia</article-title><source>Med. J. Aust.</source><year>2003</year><volume>178</volume><fpage>S67</fpage><lpage>S70</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2003.tb05311.x</pub-id><pub-id pub-id-type="pmid">12720526</pub-id></element-citation></ref><ref id="B84-antioxidants-12-01484"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Bortolasci</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders</article-title><source>Neurosci. Biobehav. Rev.</source><year>2021</year><volume>125</volume><fpage>244</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.02.037</pub-id><pub-id pub-id-type="pmid">33657433</pub-id></element-citation></ref><ref id="B85-antioxidants-12-01484"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sankaranarayanan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Castle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>C.</given-names></name></person-group><article-title>Serum lipids and suicidality among patients with schizophrenia</article-title><source>Schizophr. Res.</source><year>2020</year><volume>215</volume><fpage>479</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2019.10.004</pub-id><pub-id pub-id-type="pmid">31611043</pub-id></element-citation></ref><ref id="B86-antioxidants-12-01484"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nandeesha</surname><given-names>H.</given-names></name><name name-style="western"><surname>Keshri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rajappa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V.</given-names></name></person-group><article-title>Association of hyperglycaemia and hyperlipidaemia with cognitive dysfunction in schizophrenia spectrum disorder</article-title><source>Arch. Physiol. Biochem.</source><year>2023</year><volume>129</volume><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1080/13813455.2020.1839500</pub-id><pub-id pub-id-type="pmid">33142080</pub-id></element-citation></ref><ref id="B87-antioxidants-12-01484"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.F.</given-names></name></person-group><article-title>Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan</article-title><source>Schizophr. Res.</source><year>2005</year><volume>80</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2005.05.001</pub-id><pub-id pub-id-type="pmid">15964176</pub-id></element-citation></ref><ref id="B88-antioxidants-12-01484"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>McCutcheon</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Vano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arumuham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hindley</surname><given-names>G.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Natesan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Efthimiou</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cipriani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis</article-title><source>Lancet Psychiatry</source><year>2020</year><volume>7</volume><fpage>64</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(19)30416-X</pub-id><pub-id pub-id-type="pmid">31860457</pub-id><pub-id pub-id-type="pmcid">PMC7029416</pub-id></element-citation></ref><ref id="B89-antioxidants-12-01484"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepping</surname><given-names>P.</given-names></name><name name-style="western"><surname>Delieu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mellor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Hunter-Lavin</surname><given-names>C.</given-names></name></person-group><article-title>Antipsychotic medication and oxidative cell stress: A systematic review</article-title><source>J. Clin. Psychiatry</source><year>2011</year><volume>72</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.4088/JCP.09r05268yel</pub-id><pub-id pub-id-type="pmid">20673558</pub-id></element-citation></ref><ref id="B90-antioxidants-12-01484"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>H.A.</given-names></name></person-group><article-title>Neuroprotective effects of the second generation antipsychotics</article-title><source>Schizophr. Res.</source><year>2019</year><volume>208</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2019.04.009</pub-id><pub-id pub-id-type="pmid">30982644</pub-id></element-citation></ref><ref id="B91-antioxidants-12-01484"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furlong</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Jarvik</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>L.G.</given-names></name></person-group><article-title>Pharmacogenomic considerations of the paraoxonase polymorphisms</article-title><source>Pharmacogenomics</source><year>2002</year><volume>3</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1517/14622416.3.3.341</pub-id><pub-id pub-id-type="pmid">12052142</pub-id></element-citation></ref><ref id="B92-antioxidants-12-01484"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.C.</given-names></name></person-group><article-title>Paraoxonase gene polymorphisms, oxidative stress, and diseases</article-title><source>J. Mol. Med.</source><year>2003</year><volume>81</volume><fpage>766</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1007/s00109-003-0481-4</pub-id><pub-id pub-id-type="pmid">14551701</pub-id></element-citation></ref><ref id="B93-antioxidants-12-01484"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Boll</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rigobello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?</article-title><source>Curr. Neuropharmacol.</source><year>2019</year><volume>17</volume><fpage>1004</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.2174/1570159X17666181227164947</pub-id><pub-id pub-id-type="pmid">30592255</pub-id><pub-id pub-id-type="pmcid">PMC7052826</pub-id></element-citation></ref><ref id="B94-antioxidants-12-01484"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Supasitthumrong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michelin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>de Oliveira Semeao</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Lima Pedrao</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Kanchanatawan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>D.S.</given-names></name></person-group><article-title>Deficit schizophrenia and its features are associated with PON1 Q192R genotypes and lowered paraoxonase 1 (PON1) enzymatic activity: Effects on bacterial translocation</article-title><source>CNS Spectr.</source><year>2021</year><volume>26</volume><fpage>406</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1017/S1092852920001388</pub-id><pub-id pub-id-type="pmid">32638685</pub-id></element-citation></ref><ref id="B95-antioxidants-12-01484"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Detraux</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Winkel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name></person-group><article-title>Metabolic and cardiovascular adverse effects associated with antipsychotic drugs</article-title><source>Nat. Rev. Endocrinol.</source><year>2011</year><volume>8</volume><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.156</pub-id><pub-id pub-id-type="pmid">22009159</pub-id></element-citation></ref><ref id="B96-antioxidants-12-01484"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Detraux</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Lepeleire</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name></person-group><article-title>Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder</article-title><source>World Psychiatry</source><year>2015</year><volume>14</volume><fpage>119</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1002/wps.20204</pub-id><pub-id pub-id-type="pmid">26043321</pub-id><pub-id pub-id-type="pmcid">PMC4471960</pub-id></element-citation></ref><ref id="B97-antioxidants-12-01484"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rotella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cassioli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calderani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lazzeretti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ragghianti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ricca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mannucci</surname><given-names>E.</given-names></name></person-group><article-title>Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials</article-title><source>Eur. Neuropsychopharmacol.</source><year>2020</year><volume>32</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2019.12.118</pub-id><pub-id pub-id-type="pmid">31917068</pub-id></element-citation></ref><ref id="B98-antioxidants-12-01484"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taipale</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mehtala</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vattulainen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J.</given-names></name></person-group><article-title>20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)</article-title><source>World Psychiatry</source><year>2020</year><volume>19</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1002/wps.20699</pub-id><pub-id pub-id-type="pmid">31922669</pub-id><pub-id pub-id-type="pmcid">PMC6953552</pub-id></element-citation></ref><ref id="B99-antioxidants-12-01484"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.C.</given-names></name></person-group><article-title>Risk factors for early circulatory mortality in patients with schizophrenia</article-title><source>Psychiatry Res.</source><year>2018</year><volume>267</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2018.05.044</pub-id><pub-id pub-id-type="pmid">29879603</pub-id></element-citation></ref><ref id="B100-antioxidants-12-01484"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Crow</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Meek</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>J.E.</given-names></name></person-group><article-title>Racial differences in paraoxonase-1 (PON1): A factor in the health of southerners?</article-title><source>Environ. Health Perspect.</source><year>2009</year><volume>117</volume><fpage>1226</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1289/ehp.0900569</pub-id><pub-id pub-id-type="pmid">19672401</pub-id><pub-id pub-id-type="pmcid">PMC2721865</pub-id></element-citation></ref><ref id="B101-antioxidants-12-01484"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woudberg</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Goedecke</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Blackhurst</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frias</surname><given-names>M.</given-names></name><name name-style="western"><surname>James</surname><given-names>R.</given-names></name><name name-style="western"><surname>Opie</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Lecour</surname><given-names>S.</given-names></name></person-group><article-title>Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution</article-title><source>Lipids Health Dis.</source><year>2016</year><volume>15</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/s12944-016-0257-9</pub-id><pub-id pub-id-type="pmid">27169717</pub-id><pub-id pub-id-type="pmcid">PMC4866302</pub-id></element-citation></ref><ref id="B102-antioxidants-12-01484"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thyagarajan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Carr</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Alozie</surname><given-names>O.</given-names></name><name name-style="western"><surname>Steffes</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Kailash</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>M.D.</given-names></name></person-group><article-title>Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: The Coronary Artery Risk Development in Young Adults (CARDIA) study</article-title><source>Clin. Chem.</source><year>2008</year><volume>54</volume><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2007.099044</pub-id><pub-id pub-id-type="pmid">18281420</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antioxidants-12-01484-f001" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA 2020 flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g001.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f002" orientation="portrait"><label>Figure 2</label><caption><p>Paraoxonase activity in patients with schizophrenia and healthy controls. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g002.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f003" orientation="portrait"><label>Figure 3</label><caption><p>Sensitivity analysis of the association between paraoxonase activity and schizophrenia. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g003.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f004" orientation="portrait"><label>Figure 4</label><caption><p>Funnel plot of paraoxonase activity and schizophrenia after &#8220;trimming-and-filling&#8221;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g004.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f005" orientation="portrait"><label>Figure 5</label><caption><p>Association between the effect size of paraoxonase activity and patient/control age ratio (<bold>A</bold>), and cumulative meta-analysis of paraoxonase activity based on patient/control age ratio (<bold>B</bold>). (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g005.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f006" orientation="portrait"><label>Figure 6</label><caption><p>Association between the effect size of paraoxonase activity and patient/control HDL&#8211;cholesterol ratio (<bold>A</bold>), and cumulative meta-analysis of paraoxonase activity based on patient/control HDL&#8211;cholesterol ratio (<bold>B</bold>). (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g006.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f007" orientation="portrait"><label>Figure 7</label><caption><p>Paraoxonase activity in schizophrenic patients and healthy controls according to study country. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g007.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f008" orientation="portrait"><label>Figure 8</label><caption><p>Paraoxonase activity in schizophrenic patients and healthy controls according to pharmacological treatment of schizophrenia. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g008.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f009" orientation="portrait"><label>Figure 9</label><caption><p>Arylesterase activity in patients with schizophrenia and healthy controls. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g009.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f010" orientation="portrait"><label>Figure 10</label><caption><p>Sensitivity analysis of the association between arylesterase activity and schizophrenia. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g010.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f011" orientation="portrait"><label>Figure 11</label><caption><p>Funnel plot of the association between arylesterase activity and schizophrenia after &#8220;trimming-and-filling&#8221;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g011.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f012" orientation="portrait"><label>Figure 12</label><caption><p>Association between the effect size of arylesterase activity and patient/control age ratio (<bold>A</bold>), and cumulative meta-analysis of arylesterase activity based on patient/control age ratio (<bold>B</bold>). (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g012.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f013" orientation="portrait"><label>Figure 13</label><caption><p>Association between the effect size of arylesterase activity and patient/control body mass index ratio (<bold>A</bold>), and cumulative meta-analysis of arylesterase activity based on patient/control body mass index ratio (<bold>B</bold>). (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g013.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f014" orientation="portrait"><label>Figure 14</label><caption><p>Association between the effect size of arylesterase activity and patient/control HDL&#8211;cholesterol ratio (<bold>A</bold>), and cumulative meta-analysis of arylesterase activity based on patient/control HDL&#8211;cholesterol ratio (<bold>B</bold>). (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g014.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f015" orientation="portrait"><label>Figure 15</label><caption><p>Arylesterase activity in schizophrenic patients and healthy controls according to study country. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g015.jpg"/></fig><fig position="float" id="antioxidants-12-01484-f016" orientation="portrait"><label>Figure 16</label><caption><p>Arylesterase activity in schizophrenic patients and healthy controls according to pharmacological treatment of schizophrenia. (a) and (b) refer to different arms of the same study [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>,<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>,<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>,<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>,<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>,<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>,<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>,<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>,<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>,<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-12-01484-g016.jpg"/></fig><table-wrap position="float" id="antioxidants-12-01484-t001" orientation="portrait"><object-id pub-id-type="pii">antioxidants-12-01484-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of the selected studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Controls</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Patients with Schizophrenia</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (Years)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/F</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PON Mean &#177; SD (U/L)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARE Mean &#177; SD (kU/L)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HDL Mean (mg/dL or mmol/L)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (Years)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M/F</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PON Mean &#177; SD (U/L)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARE Mean &#177; SD (kU/L)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HDL Mean (mg/dL or mmol/L)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarandol A. et al. (a), 2007, Turkey [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246 &#177; 90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98 &#177; 37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18/22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">199 &#177; 95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 &#177; 40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarandol A. et al. (b) 2007, Turkey [<xref rid="B61-antioxidants-12-01484" ref-type="bibr">61</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246 &#177; 90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98 &#177; 37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">226 &#177; 121</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82 &#177; 40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yegin A. et al., 2012, Turkey [<xref rid="B62-antioxidants-12-01484" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.7 &#177; 44.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164 &#177; 66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.9 &#177; 61.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 &#177; 59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unsal C. et al. (a), 2013, Turkey [<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">222 &#177; 91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14/15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">220 &#177; 93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unsal C. et al. (b), 2013, Turkey [<xref rid="B63-antioxidants-12-01484" ref-type="bibr">63</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">222 &#177; 91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15/20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131 &#177; 50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gilca M. et al. (a), 2014, Romania [<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.0 &#177; 1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.4 &#177; 9.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.5 &#177; 3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121.0 &#177; 14.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gilca M. et al. (b), 2014, Romania [<xref rid="B64-antioxidants-12-01484" ref-type="bibr">64</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.0 &#177; 1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.4 &#177; 9.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.6 &#177; 2.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123.6 &#177; 12.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mabrouk H. et al., 2014, Tunisia [<xref rid="B65-antioxidants-12-01484" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64/55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">290 &#177; 171</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">140</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116/24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">239 &#177; 176</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brinholi F.F. et al., 2015, Brazil [<xref rid="B66-antioxidants-12-01484" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32/29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237.8 &#177; 58.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36/15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">212.2 &#177; 56.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hussein O. et al. (a), 2015, Israel [<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.3 &#177; 37.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 &#177; 22.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hussein O. et al. (a), 2015, Israel [<xref rid="B67-antioxidants-12-01484" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.3 &#177; 37.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.1 &#177; 22.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarandol A. et al. (a), 2015, Turkey [<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186 &#177; 75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.7 &#177; 37.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">198 &#177; 107</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.4 &#177; 36.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarandol A. et al. (b), 2015, Turkey [<xref rid="B68-antioxidants-12-01484" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186 &#177; 75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.7 &#177; 37.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209 &#177; 107</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.9 &#177; 29.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gunes M. et al., 2016, Turkey [<xref rid="B69-antioxidants-12-01484" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.9 &#177; 5.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114.5 &#177; 24.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.6 &#177; 3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135 &#177; 24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kulaksizoglu B. et al., 2016, Turkey [<xref rid="B70-antioxidants-12-01484" ref-type="bibr">70</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.1 &#177; 28.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36/28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.7 &#177; 21.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boll K.M. et al., 2017, Brazil [<xref rid="B72-antioxidants-12-01484" ref-type="bibr">72</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74/44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">178.6 &#177; 58.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85/40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">181.6 &#177; 47.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atagun M.I. et al., 2018, Turkey [<xref rid="B71-antioxidants-12-01484" ref-type="bibr">71</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20/23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186 &#177; 75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215 &#177; 52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19/18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">154 &#177; 93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">202 &#177; 48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.27</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paval D. et al., 2018, Romania [<xref rid="B73-antioxidants-12-01484" ref-type="bibr">73</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12/22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112 &#177; 51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42/18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97 &#177; 26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17</td></tr></tbody></table><table-wrap-foot><fn><p>Legend: PON, paraoxonase-1; ARE, arylesterase; HDL, high-density lipoprotein cholesterol; M, male; F, female; NR, not reported. (a) and (b) refer to different arms of the same study.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>